HWM
STRO icon

HighMark Wealth Management’s Sutro Biopharma STRO Stock Holding History

HighMark Wealth Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$763 Hold
23
– – ﹤0.01% 508
2026
Q1 		$572 Hold
23
– – ﹤0.01% 507
2025
Q4 		$266 Hold
23
– – ﹤0.01% 558
2025
Q3 		$195 Hold
23
– – ﹤0.01% 583
2025
Q2 		$161 Hold
23
– – ﹤0.01% 593
2025
Q1 		$146 Sell
23
-202
-90% -$3.18K ﹤0.01% 556
2024
Q4 		$4.14K Hold
225
– – ﹤0.01% 395
2024
Q3 		$7.79K Hold
225
– – ﹤0.01% 331
2024
Q2 		$6.59K Hold
225
– – ﹤0.01% 349
2024
Q1 		$12.7K Hold
225
– – 0.01% 244
2023
Q4 		$9.65K Hold
225
– – 0.01% 267
2023
Q3 		$7.81K Sell
225
-33
-13% -$1.44K 0.01% 288
2023
Q2 		$12K Hold
258
– – 0.01% 240
2023
Q1 		$11.9K Sell
258
-10
-4% -$635 0.01% 273
2022
Q4 		$21.6K Sell
268
-130
-33% -$9.04K 0.02% 164
2022
Q3 		$22K Sell
398
-60
-13% -$3.55K 0.02% 153
2022
Q2 		$24K Hold
458
– – 0.02% 145
2022
Q1 		$38K Hold
458
– – 0.03% 125
2021
Q4 		$68K Sell
458
-103
-18% -$18.5K 0.04% 99
2021
Q3 		$106K Buy
561
+14
+3% +$2.66K 0.08% 75
2021
Q2 		$102K Buy
547
+418
+324% +$81.8K 0.08% 75
2021
Q1 		$29K Buy
129
+60
+87% +$14.2K 0.02% 144
2020
Q4 		$15K Buy
+69
New +$11.4K 0.01% 184

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

HighMark Wealth Management's STRO Position: Q2 2026 in Review

HighMark Wealth Management held its Sutro Biopharma (STRO) position steady in Q2 2026 at 23 shares worth $763. The position accounts for ﹤0.01% of the portfolio, ranked #508.

HighMark Wealth Management first reported a position in STRO in Q4 2020 and has held it in 23 quarters since. The position peaked at $106K in Q3 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • HighMark Wealth Management held 23 shares of Sutro Biopharma worth $763 as of Q2 2026.
  • HighMark Wealth Management left its Sutro Biopharma share count unchanged in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #508 holding.
  • HighMark Wealth Management first reported a position in Sutro Biopharma in Q4 2020 and has held it in 23 quarters since.
  • HighMark Wealth Management's Sutro Biopharma position peaked at $106K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.